Life Sciences Venture Capital Monitor - May 2020 FCF Fox Corporate Finance | FCF Life Sciences - FCF Fox ...
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
FCF Fox Corporate Finance | FCF Life Sciences Life Sciences Venture Capital Monitor May 2020 Antibody Part of FCF Life Sciences Research Series Strategic Financing Advisory in Life Sciences
Agenda
F C F L i f e S c i e nc e s O v e r v i ew
2Overview
Overview Service Portfolio Facts and Figures
Focus on Biotechnology, MedTech and HealthTech Over Over
Life Sciences Life Sciences
Management Team of 100 years EUR 2bn
FCF advises innovative companies on arranging, structuring and placing Advisory in aggregated Life Sciences
Presentation ~10
equity and debt transactions in a holistic financing strategy approach. Board Life Sciences transaction
Integrated based in Munich
Together with its industry advisors, FCF Life Sciences provides valuable experience volume1
Financial
support on the strategic positioning of its clients Modeling
Post- Over 4
Access to
Strategic Financing Advisory Transaction 80 Leading regularly
Support > 1000
completed Life EIB advisor published Life
international
FCF advises with its dedicated Life Sciences team on the following Investor Sciences in Europe Sciences
investors
transaction types: Screening transactions1 reports
1 comprising Professionals and Advisory Board
Investor / IB
Venture Capital Venture Debt Roadshow
+ +
Life Sciences Research Series
Growth Equity Due
Diligence
Support Venture Capital Monitor Public Equity Monitor
Equity & Debt is a monthly is the most detailed
Life Sciences Team Fundraising
published overview analysis of
Financing of venture capital European publicly
Strategy listed companies,
transactions of Life
Advisory
Sciences companies from the Life
Closing Sciences sectors
Dr. Holger Bengs Prof. Dr. Elijah Falk Arno Fuchs Dr. Alexandra Goll
Assistance
Founder & CEO Horst Domdey Analyst CEO Former
BCNP Consultants Co-Founder of Medigene General Partner
TVM Capital
Term Sheet
& board member BioM Venture Capital Report IPO Report
Negotiation
analyses the latest examines recent
IPO
Execution Venture Capital IPO trends in the
Support funding activities in Life Sciences sector,
Life
Science the Life Sciences with a strong focus
Yasmin Claus Schalper Dr. Mathias Sebastian Enno Spillner Advisory sector in Europe on the comparison
Herrmann Co-Founder & former Schott Sommer CFO Evotec Board (extract from
Analyst CFO Pieris Pharma Director Associate service portfolio) and the US of European and US
characteristics
3Executive Summary
The FCF Life
FCF Life Sciences Venture Capital Monitor Recipients
Sciences Venture
Capital Monitor is a is a monthly published overview of biotechnology, pharmaceutical, The FCF Life Sciences Venture Capital Monitor targets the following
monthly published medical technology and healthcare technology companies, recipients:
overview focusing on displaying venture capital financing trends in the European life ▪ Corporates / Executives ▪ Venture capital investors
the venture capital science industry ▪ Institutional investors ▪ Family Offices / High-
financing ▪ Private equity investors net-worth individuals
environment in the ▪ Advisors
biotechnology, Scope
pharmaceutical,
medical technology The selection of companies is based on the following criteria: Availability
and healthcare
technology ▪ Focus on transactions with European headquartered life science The FCF Life Sciences Venture Capital Monitor is available on FCF’s
segments, and can companies and available deal volume website at “https://www.fcf.de/de/research/life-science-research“
be used as a quick ▪ Companies operating in the biotechnology, pharmaceutical,
reference for medical technology, healthcare technology, services or other life Data
investors, corporates science related sectors
and professionals All input data is provided by Pitchbook or GlobalData and is not
▪ The therapeutics sector is further divided into the following independently verified by FCF. Ratio and multiple calculations are
indications: Oncology, Cardiovascular, Central Nervous System, driven based on the input data available. For additional information
Gastrointestinal, Hematological, Infectious Diseases, and disclaimer, please refer to the last page
More advanced, Immunology, Metabolic, Ophthalmology, Rare Diseases,
detailed and / or Respiratory, Diversified and Others
customized reports
are available upon
request To recommend colleagues or fellow investors to be added to the If you have questions, comments or ideas, please do not hesitate
mailing list, kindly send an email with the respective contact to contact us
information
4Agenda
V e n t ur e C a p i t a l T r a n s a c t i ons
May 2020
5European Venture Capital Transactions in Life Sciences
May 2020
Deal Total
Vertical - Volume Raised
Overview (YTD) # Date Company HQ Subsector Indication / Stage Company Description Series (EURm) (EURm) Deal Synopsis
Cumulative Financing Volume (EURm)
Developer of a health management
6,000 Self-Care / The company raised $301.83 million of venture funding in the form of convertible debt
1 28-05-20 LumiraDx GBR HealthTech software designed to transform patient - 278 555
On market on May 28, 2020.
5,000 care.
4,000 3,027
3,000
2,000
Orthodontics
1,000 2020 Provider of orthodontics solutions intended
2 28-05-20 PlusDental DEU MedTech solutions / - 32 42 The company raised EUR 32 million of venture funding on May 28, 2020.
2019 for the healthcare industry.
0 Developing
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
Financing Volume (May 2020): EUR 791m
Subsectors Indications1
3D printing system
Healthcare
for industrial and
Services Developer of a 3D printing system created
3 28-05-20 Kumovis DEU MedTech medical A 4 5 The company raised EUR 3.6 million of Series A venture on May 28, 2020.
MedTech for industrial and medical applications.
Oncology applications /
Others
4% On market
14% 25%
28%
EUR EUR
3,027m 54% Biotech / 1,655m
28% Pharma 5%
Genetic 18% Central Sound technology Developer of a sound technology designed The company raised EUR 2.3 million of Series A venture on May 28, 2020. The
Disorders 9% Nervous 4 28-05-20 IntendiMe ITA HealthTech application / to help deaf people detect objects and A 2 3 funding will be used by the startup to enter the market, increase R&D activities, and
15% System
HealthTech
Gastro-
On market sounds. hire more team members.
intestinal
Immunology
Top Company Origins Top Investor Origins Healthcare
Digital health Operator of a digital health company The company raised EUR 45 million of Series C venture on May 27, 2020. The funds
5 27-05-20 Doktor.se SWE platform / intended to streamline and create better C 45 83 will be used for expanding its digital operations and physical clinics to meet growing
Services
Others On market access to Swedish healthcare. demand, and to lay the groundwork for international expansion.
Others
21% 25%
EUR 39% EUR 43%
8%
3,027m 5% 3,027m Developer of glycan targeted carbohydrate-
The company raised GBP 4 million of venture funding on May 27, 2020. The funds will
8% 8% Biotech / Oncology / binding modules intended to focus on the
6 27-05-20 Pneumagen GBR - 5 6 be used for the clinical development of Neumifil for the prevention and treatment of
12% 8% Pharma Pre-clinic treatment of respiratory tract infections
12% 11% COVID-19.
(RTIs) and cancer.
Top 5 Deals Top 5 Investors
Deal # of Deal
# Company HQ Volume Series # Investor HQ Deals Volume2
Central Nervous Developer of gene therapies designed for The company raised $222.7 million of Series A venture on May 26, 2020. The funds
Arvelle Biotech /
7 26-05-20 CHE System / the treatment of partial-onset seizures in A 205 205 will be used to continue to expand the company's operations across Europe, including
Therapeutics Pharma
1 LumiraDx 278 - 1 Bpifrance 13 28 In filing adult patients. key country-by-country hires in preparation of the European launch of cenobamate.
Arvelle High-Tech
2 205 A 2 7 7
Therapeutics Gründerfonds
Oxford
BioInnovation
3 Nanopore 186 - 3 6 4
Institute (BII) The company raised GBP 49 million of Series C venture funding on May 26, 2020. The
Technologies Developer of automated drug discovery
Biotech / Other / funds will be used by the company to expand its existing portfolio and pipeline, by
4 Investiere 5 9 8 26-05-20 Exscientia GBR technologies intended to improve the C 56 97
4 AM-Pharma 163 - Pharma On market launching new projects, progressing advanced projects to the clinic, and expanding AI
medicine development process.
biology as part of its full-stack capabilities.
5 Immunocore 154 B 5 Almi Invest 5 1
Source: PitchBook as of 08.06.2020; FCF Equity Research; GlobalData
Note: All volumes in EURm; financing rounds without deal values are excluded 6
1Only includes biotechnology and pharmaceutical deals; 2 Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round)European Venture Capital Transactions in Life Sciences
May 2020
Deal Total
Vertical - Volume Raised
Overview (YTD) # Date Company HQ Subsector Indication / Stage Company Description Series (EURm) (EURm) Deal Synopsis
Cumulative Financing Volume (EURm)
Point-of-care Developer of an automated point-of-care The company raised EUR 16.3 million of Series B venture on May 26, 2020. The
6,000
9 26-05-20 Spindiag DEU MedTech screening system / system designed to offer a sustainable B 16 21 funding raised will be used to enable the market launch of the innovative Rhonda
5,000 On market platform for diagnosing infectious diseases. diagnostic platform for the detection of the SARS-CoV-2 virus.
4,000 3,027
3,000
2,000
Central Nervous Developer of drugs intended to treat
1,000 2020 Accure Biotech /
10 26-05-20 ESP System / diseases related to the Central Nervous A 8 8 The company raised EUR 7.6 million of Series A venture funding on May 26, 2020.
2019 Therapeutics Pharma
0 Phase I System (CNS).
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
Financing Volume (May 2020): EUR 791m
Subsectors Indications1
Healthcare The company raised EUR 2.3 million of Series A venture funding on May 25, 2020.
Services Biotech / Oncology / Operator of biopharmaceutical company The funds will be used to advance the preclinical development of TL-532: Tollys will
11 25-05-20 Tollys FRA A 2 6
MedTech Pharma On market intended to cure cancer-related disease. notably use the funding to produce TL-532 and to launch the regulatory safety studies
Oncology required before clinical trials in bladder cancer planned by the end 2021 / early 2022.
Others
4%
14% 25%
28%
EUR EUR
3,027m 54% Biotech / 1,655m
28% Pharma 5%
Genetic 18% Central Central Nervous Operator of a biotechnology company The company raised CHF 2 million of angel on May 25, 2020. The funds will be used
9% Nervous Biotech /
Disorders 12 25-05-20 GliaPharm CHE System / intended to develop new approaches to - 2 2 to advance its drug development program and generate key preclinical data for the
15% System Pharma
HealthTech
Gastro-
Discovery treat neurological diseases. next anticipated round of financing.
intestinal
Immunology
Top Company Origins Top Investor Origins Healthcare
Cloud-based IoT Provider of a cloud-based IoT service
13 22-05-20 Tellu NOR service / designed to innovate smart solutions for - 4 4 The company raised NOK 40 million of venture on May 22, 2020.
Services
Others On market eHealth and personnel safety.
Others
21% 25%
EUR 39% EUR 43%
8%
3,027m 5% 3,027m
Developer of clinical trial systems designed
8% 8% Bio-Images Drug Biotech / Other /
14 22-05-20 GBR to activate and accelerate product -European Venture Capital Transactions in Life Sciences
May 2020
Deal Total
Vertical - Volume Raised
Overview (YTD) # Date Company HQ Subsector Indication / Stage Company Description Series (EURm) (EURm) Deal Synopsis
Cumulative Financing Volume (EURm)
Metabolic
6,000 Biotech / Developer of proprietary drug formulas The company raised PLN 7 million of venture funding on May 20, 2020. The funds will
17 20-05-20 Biotts POL Disorders / - 2 2
Pharma intended for anti-diabetes therapies. be used for development, team building and patent protection.
5,000 Pre-clinic
4,000 3,027
3,000
2,000
Operator of a medtech company intended
1,000 2020 Sarissa Biosensors / to develop novel biosensors for use in The company raised GBP 1.2 million of venture funding on May 20, 2020, putting the
18 20-05-20 GBR MedTech - 1 5
2019 Biomedical Developing Point-of-Care in-vitro diagnostic (PoC IVD) company's pre-money valuation at GBP 2.99 million.
0 applications.
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
Financing Volume (May 2020): EUR 791m
Subsectors Indications1
Healthcare
Elderly care
Services Healthcare Provider of elderly care services intended The company raised EUR 350,000 of venture funding on May 20, 2020. The funding
19 20-05-20 Time for You Care GBR services / -European Venture Capital Transactions in Life Sciences
May 2020
Deal Total
Vertical - Volume Raised
Overview (YTD) # Date Company HQ Subsector Indication / Stage Company Description Series (EURm) (EURm) Deal Synopsis
Cumulative Financing Volume (EURm) Medical
technology devices Developer of medical technology devices
6,000
25 12-05-20 AorticLab ITA MedTech to treat aortic valve designed to treat patients suffering from -European Venture Capital Transactions in Life Sciences
May 2020
Deal Total
Vertical - Volume Raised
Overview (YTD) # Date Company HQ Subsector Indication / Stage Company Description Series (EURm) (EURm) Deal Synopsis
Cumulative Financing Volume (EURm) Developer of implantable bio-artificial
Bio-artificial
6,000 medical devices designed to enhance drug The company raised EUR 1.8 million of venture funding on May 4, 2020. The funds will
33 04-05-20 Defymed FRA MedTech medical devices / - 2 16
delivery systems for diverse therapeutic be used to launch the clinical phase of ExOlin.
5,000 On market
applications.
4,000 3,027
3,000
2,000 Developer of an end-to-end digital platform The company raised GBP 700,000 of venture funding on May 4, 2020, putting the
End-to-end digital
1,000 2020 Bond Digital that enhances lateral flow tests and company's pre-money valuation at GBP 4.3 million. The funds will be used to develop
34 04-05-20 GBR HealthTech platform / -Contact Details & Disclaimer
DISCLAIMER
This document does not constitute an offer or invitation to purchase or
subscribe for any securities, and neither this document nor anything contained
herein shall form the basis of or may be relied upon in connection with any
contract or commitment whatsoever. No representation or warranty (express or
FCF Fox Corporate Finance GmbH implied) is made as to, and no reliance should be placed on, any information,
including projections, estimates, targets and opinions, contained herein, and no
Maximilianstrasse 12-14 ▪ 80539 Munich ▪ Germany liability whatsoever is accepted as to any errors, omissions or misstatements
Telephone +49 (89) 206 0409-0 ▪ Facsimile +49 (89) 206 0409-299 contained herein, and, accordingly, neither FCF nor any of its officers, directors
info@fcf.de ▪ www.fcf.de or employees accepts any liability whatsoever arising directly or indirectly from
the use of this document. By accepting this document you acknowledge that
you will be solely responsible for your own assessment of the market and the
market position of the Company and that you will conduct your own analysis
and be solely responsible for forming your own view of the potential future
Arno Fuchs Dr. Mathias Schott performance of the Company's business. This document contains certain
Chief Executive Officer Director
forward-looking statements, including assumptions, opinions and views cited
P: +49 (89) 206 0409-100 P: +49 (89) 206 0409-123 from third party sources. Various known and unknown risks, uncertainties and
M: +49 (172) 863 6777 M: +49 (174) 301 1846
other factors could cause the actual results, financial position, development or
arno.fuchs@fcf.de mathias.schott@fcf.de
performance of the Company to differ materially from the estimations
expressed or implied herein. FCF does not guarantee that the figures,
assumptions and calculations underlying such historical and forward looking
Sebastian Sommer Alexander Kuhn statements are free from errors nor does FCF accept any responsibility for the
Associate Analyst
future accuracy of the opinions expressed in this document or the actual
P: +49 (89) 206 0409-130 P: +49 (89) 206 0409-120 occurrence of the forecasted developments.
M: +49 (172) 839 5738 M: +49 (173) 590 6671
sebastian.sommer@fcf.de alexander.kuhn@fcf.de © FCF Fox Corporate Finance GmbH 2020
11THE FINANCING SPECIALIST
You can also read
